Developer docs
API playgroundTry for free, no card

Search company profiles

Freespira, Inc.

Full company profile

uuid0000ket

Namestring
Freespira, Inc.
Legal namestring
Freespira, Inc.
Websiteurl
freespira.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Freespira, Inc. is a privately held digital therapeutics company founded in 2013 and headquartered in Kirkland, Washington. The company has developed the only FDA-cleared digital therapeutic that targets the physiological underpinnings of panic disorder and post-traumatic stress disorder (PTSD) — specifically dysregulated breathing patterns and CO2 hypersensitivity — through capnometry-guided respiratory intervention (CGRI). Its product, now in its fifth-generation hardware form (FST5), pairs a proprietary NDIR CO2 sensor and nasal cannula with a connected tablet providing real-time audio/visual biofeedback, plus dedicated human coaching. Patients complete a structured 28-day protocol of two daily 17-minute sessions, with results showing 73-86% panic-attack-free rates immediately post-treatment and 71-80% sustained reductions at 12 months.

The underlying technology stack combines a medical-grade breathing sensor, embedded firmware, a guided software experience, and a licensed clinical coaching layer. The platform has accumulated three FDA 510(k) clearances (panic disorder K131586 in 2013, PTSD K180173 in 2018, and adolescent expansion K233337 in May 2025), and clinical evidence spans 6,000+ patients across multiple peer-reviewed studies.

Freespira's business model is built on B2B2C distribution with three primary revenue channels: (1) health plan and self-insured employer benefit coverage under multi-year subscription contracts with outcomes-based pricing, including a recently launched "Zero Risk" program offering 1:1 ROI guarantees; (2) VA federal procurement via Lovell Government Services on the Federal Supply Schedule (FSS 65IIA #V797D-50450); and (3) direct-to-consumer self-referral with self-pay, HSA/FSA, or interest-free payment options. Named customers include Highmark BCBS, Point32Health (2.2M members), WellCare of Kentucky Medicaid (450,000 members; 12% estimated eligible), Security Health Plan, Brighton Marine Health Plan, and the VA, collectively covering approximately 40 million lives.

Short descriptiontext

Freespira develops an FDA-cleared digital therapeutic that uses capnometry-guided breathing retraining to reduce or eliminate panic disorder and PTSD symptoms in a 28-day at-home protocol, serving health plans, self-insured employers, the VA, and individual patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKirkland, United States
HQ citystring
Kirkland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, panic disorder treatment, PTSD treatment, respiratory biofeedback therapy, prescription digital therapeutics
Industry3 codes
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALACAE
Chronic Condition Virtual Care & Disease Management (Payer-Sponsored)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms
NAICS code2 codes
  • Home Health Care Services62161
  • Home Health Care Services621610
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Prepackaged Software7372
Product category
Digital Therapeutics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Health Plan and Employer Benefit Coverage
TypeSubscription Recurring
Description

Freespira is covered by health plans and self-insured employers as a medical benefit. Health plans and employers pay per-enrolled member or per-completed-treatment under outcomes-based pricing arrangements. The Zero Risk program offers performance guarantees (1:1 ROI) and outcomes-based pricing.

freespira.com
2VA Federal Procurement
TypeHardware Sales
Description

Freespira is listed on the Federal Supply Schedule (65IIA: V797D-50450) through SDVOSB partner Lovell Government Services. VA pays for treatments authorized through VA procurement processes.

freespira.com
3Self-Pay / HSA/FSA / Payment Plans
TypeOne Time License
Description

Patients without insurance coverage can use HSA/FSA accounts or enroll in an interest-free payment plan. Self-pay provides an alternative revenue stream for individual consumers.

freespira.com
4Outcomes-Based / Performance Pricing
TypeUsage Based
Description

The Zero Risk program for health plans ties full payment to clinical outcome benchmarks. Health plans only pay full price for members who achieve defined clinical improvement thresholds.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain
Pricing details4 tiers
1Insurance/Health Plan Covered
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Most major health plans and PBMs cover Freespira as a medical benefit. Coverage varies by plan; some members pay no additional cost, others have cost-sharing.

freespira.com
2VA-Covered Veterans
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Eligible veterans can access Freespira through VA benefits at no cost. VA providers submit consults via Lovell Government Services on the Federal Supply Schedule.

freespira.com
3Self-Pay / HSA/FSA
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Patients without insurance can use HSA/FSA accounts or enroll in an interest-free payment plan. No specific price disclosed.

freespira.com
4Outcomes-Based Pricing (Zero Risk Program)
ModelOutcome Based/ PerformanceBilling cadenceAnnual
Notes

Under the Zero Risk program for health plans, pricing is tied to clinical outcomes. Health plans receive a 1:1 ROI performance guarantee in Year 1, and pay full price only for members achieving clinical outcome benchmarks.

prnewswire.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Freespira develops and sells an FDA-cleared at-home digital therapeutic that combines a proprietary breathing sensor, integrated tablet with real-time capnometry feedback software, and Care Specialist coaching to normalize dysfunctional breathing patterns and reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD in a 28-day protocol. The bundled treatment kit is shipped directly to patients' homes and is covered as a medical benefit by health plans, self-insured employers, and the VA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Over 80% of patients experienced significant symptom reduction post-treatment (panic disorder and PTSD combined)
+7 more records
Product overview1 text field

Freespira, Inc. offers a single unified digital therapeutic product—the Freespira system—for the treatment of panic disorder, panic attacks, and PTSD symptoms. The core offering consists of the Freespira hardware device (now in its fifth generation FST5) combined with a proprietary software application and coaching services. The system includes a compact breathing sensor, tablet with real-time feedback display, nasal cannula, and dedicated Care Specialist support. Treatment follows a 28-day protocol with twice-daily 17-minute sessions. After completing the program, patients receive the Freespira Tones App for continued practice. All components work together as an integrated at-home treatment solution that addresses the underlying physiological causes of anxiety disorders through breathing retraining.

Product and service2 records
1Freespira Digital Therapeutic System (FST5)
CategoryDigital Therapeutic Device
Description

FDA-cleared at-home medical device that combines a proprietary breathing sensor with an integrated display tablet to provide real-time, feedback-guided respiratory retraining for adults and adolescents with panic disorder and PTSD.

2Freespira 28-Day Treatment Protocol
CategoryDigital Therapeutic Treatment Program
Description

At-home treatment program requiring two 17-minute sessions per day for 28 days, using capnography-guided respiratory intervention (CGRI) to normalize breathing patterns and reduce or eliminate panic attacks and PTSD symptoms. Includes device kit, real-time biofeedback, virtual onboarding, and weekly Care Specialist check-ins. Indicated for adults and adolescents (ages 13+) with panic disorder or PTSD.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Freespira partnered with Brighton Marine, a nonprofit administering the US Family Health Plan (USFHP) for Southern New England, to make its FDA-cleared digital therapeutic for panic disorder and PTSD available to Brighton Marine Health Plan members. The treatment became available in November 2025, representing Brighton Marine's commitment to providing veterans and military families with innovative mental health treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

WellCare of Kentucky (a Centene Medicaid plan) launched a pilot program with Freespira providing eligible Medicaid members access to at-home digital therapeutic treatment for panic disorder and PTSD. WellCare is the first health plan in Kentucky to partner with a digital therapeutic company specializing in mental health. Analytics estimate 12% of WellCare's 450,000 Kentucky Medicaid members could benefit.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Point32Health (parent of Harvard Pilgrim Health Care and Tufts Health Plan) selected Freespira as winner of its inaugural Innovation Challenge, recognizing it as a pioneering solution for mental health outcomes and affordability. The partnership aims to pilot Freespira's treatment technology to expand mental health options for Point32Health's 2.2 million members in New England.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Highmark BCBS expanded access to Freespira's digital therapeutic for panic disorder and PTSD across its member base. A Highmark behavioral health director cited reduced medication use and healthcare cost savings as drivers for the partnership.

5Security Health Plan
Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Security Health Plan selected Freespira as a new benefit offering for members with panic disorder and PTSD, integrating it into their covered mental health treatments.

freespira.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Freespira is listed on the Federal Supply Schedule 65IIA #V797D-50450 through SDVOSB partner Lovell Government Services. Lovell facilitates VA procurement and handles the Government Services administration for Freespira's veteran treatment program. CAGE: 71G35, DUNS: 079230337, UEI: MNH3STM1FTS6.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Crossover Health is listed as a Freespira partner, likely offering the treatment to its member population through employer-sponsored health benefits.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Chorus Preferred is listed as a Freespira partner organization, potentially serving as a navigation platform or aggregator for the digital therapeutic.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Freespira is a founding member of IMPACT, the Virtual First Medical Practice Collaborative at the Digital Medicine Society, focused on advancing digital medicine and virtual-first care models.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

New Vista, a Kentucky-based organization specializing in integrated mental and physical healthcare, was designated as the key medical practice partner for WellCare of Kentucky's Freespira pilot program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Big Health develops FDA-cleared prescription digital therapeutics (Sleepio for insomnia, Daylight for anxiety) sold through health plans and employers on outcomes-based contracts. Most directly comparable to Freespira in PDT business model, payor go-to-market, and clinical evidence positioning.

TypeDirect peer
Description

Akili markets EndeavorRx, an FDA-cleared prescription digital therapeutic (for ADHD) with similar payor reimbursement and clinical evidence strategy. Closest analog to Freespira among publicly known PDTs in regulatory pathway and business model.

3Pear Therapeutics
TypeDirect peer
Description

Pear Therapeutics pioneered FDA-cleared prescription digital therapeutics (reSET, reSET-O) for substance use disorder and is the historical reference point for Freespira's PDT model, though it filed for bankruptcy in 2023 illustrating category capital risks.

TypeEmerging player
Description

Limbic is a UK-based digital mental health platform offering AI-driven CBT and emotional support tools sold to health systems and payors. Comparable to Freespira as a technology-driven mental health intervention with payor channels, though focused on a different delivery modality.

TypeEmerging player
Description

Woebot Health delivers AI chatbot-based mental health interventions with FDA Breakthrough Device designation. Comparable to Freespira as an emerging digital therapeutic in behavioral health with regulatory clearance pursuit, though software-only and consumer-focused.

TypeBroad incumbent
Description

Lyra Health is a leading mental health benefits platform for employers, bundling therapy, coaching, and digital tools. Comparable to Freespira as a payor-facing mental health vendor, but operates as a broad incumbent across the full continuum of care rather than a single therapeutic.

TypeBroad incumbent
Description

Spring Health provides employer-sponsored mental health benefits combining provider networks, coaching, and digital programs. Comparable to Freespira as a payor channel for anxiety/PTSD care, but offers a broader, integrated solution set rather than a single device-based treatment.

TypeBroad incumbent
Description

Cerebral is a subscription-based mental health platform offering telehealth psychiatry and therapy for anxiety, depression, and related conditions. Comparable to Freespira in DTC marketing and anxiety-focused positioning, though broader in scope and provider-delivered.

TypeBroad incumbent
Description

Talkspace operates an online therapy platform sold through health plans and employers. Comparable to Freespira as a payor-covered mental health service targeting anxiety and trauma-related conditions, though therapy-delivered rather than device-based.

TypeBroad incumbent
Description

BetterHelp (a Teladoc Health subsidiary) is the largest consumer-facing online therapy platform. Comparable to Freespira in serving patients with anxiety and PTSD symptoms via remote care, though broader in scope and pure-software in delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Freespira, Inc.

Digital Therapeuticsfreespira.com

Freespira develops an FDA-cleared digital therapeutic that uses capnometry-guided breathing retraining to reduce or eliminate panic disorder and PTSD symptoms in a 28-day at-home protocol, serving health plans, self-insured employers, the VA, and individual patients.

What Freespira, Inc. does

Freespira, Inc. is a privately held digital therapeutics company founded in 2013 and headquartered in Kirkland, Washington. The company has developed the only FDA-cleared digital therapeutic that targets the physiological underpinnings of panic disorder and post-traumatic stress disorder (PTSD) — specifically dysregulated breathing patterns and CO2 hypersensitivity — through capnometry-guided respiratory intervention (CGRI). Its product, now in its fifth-generation hardware form (FST5), pairs a proprietary NDIR CO2 sensor and nasal cannula with a connected tablet providing real-time audio/visual biofeedback, plus dedicated human coaching. Patients complete a structured 28-day protocol of two daily 17-minute sessions, with results showing 73-86% panic-attack-free rates immediately post-treatment and 71-80% sustained reductions at 12 months.

The underlying technology stack combines a medical-grade breathing sensor, embedded firmware, a guided software experience, and a licensed clinical coaching layer. The platform has accumulated three FDA 510(k) clearances (panic disorder K131586 in 2013, PTSD K180173 in 2018, and adolescent expansion K233337 in May 2025), and clinical evidence spans 6,000+ patients across multiple peer-reviewed studies.

Freespira's business model is built on B2B2C distribution with three primary revenue channels: (1) health plan and self-insured employer benefit coverage under multi-year subscription contracts with outcomes-based pricing, including a recently launched "Zero Risk" program offering 1:1 ROI guarantees; (2) VA federal procurement via Lovell Government Services on the Federal Supply Schedule (FSS 65IIA #V797D-50450); and (3) direct-to-consumer self-referral with self-pay, HSA/FSA, or interest-free payment options. Named customers include Highmark BCBS, Point32Health (2.2M members), WellCare of Kentucky Medicaid (450,000 members; 12% estimated eligible), Security Health Plan, Brighton Marine Health Plan, and the VA, collectively covering approximately 40 million lives.

Freespira, Inc. firmographics

Firmographics
Name
Freespira, Inc.
Legal name
Freespira, Inc.
Website
https://freespira.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Freespira develops an FDA-cleared digital therapeutic that uses capnometry-guided breathing retraining to reduce or eliminate panic disorder and PTSD symptoms in a 28-day at-home protocol, serving health plans, self-insured employers, the VA, and individual patients.
Ownership category
akta.pro rank

Freespira, Inc. industry classification

Industry
Product category
Digital Therapeutics
NAICS
Home Health Care Services (62161), Home Health Care Services (621610)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALACAE
Chronic Condition Virtual Care & Disease Management (Payer-Sponsored)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms

Keywords

  • Digital therapeutics
  • Panic disorder treatment
  • PTSD treatment
  • Respiratory biofeedback therapy
  • Prescription digital therapeutics

Where Freespira, Inc. is headquartered

Location

Headquarters

HQ city
Kirkland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Freespira, Inc. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

  1. Health Plan and Employer Benefit Coverage: Freespira is covered by health plans and self-insured employers as a medical benefit. Health plans and employers pay per-enrolled member or per-completed-treatment under outcomes-based pricing arrangements. The Zero Risk program offers performance guarantees (1:1 ROI) and outcomes-based pricing.
  2. VA Federal Procurement: Freespira is listed on the Federal Supply Schedule (65IIA: V797D-50450) through SDVOSB partner Lovell Government Services. VA pays for treatments authorized through VA procurement processes.
  3. Self-Pay / HSA/FSA / Payment Plans: Patients without insurance coverage can use HSA/FSA accounts or enroll in an interest-free payment plan. Self-pay provides an alternative revenue stream for individual consumers.
  4. Outcomes-Based / Performance Pricing: The Zero Risk program for health plans ties full payment to clinical outcome benchmarks. Health plans only pay full price for members who achieve defined clinical improvement thresholds.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractInsurance/Health Plan Covered
SubscriptionMulti-year contractVA-Covered Veterans
One time/ perpetual licensePay-as-you-goSelf-Pay / HSA/FSA
Outcome Based/ PerformanceAnnualOutcomes-Based Pricing (Zero Risk Program)

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Freespira, Inc. product offering

Product offering

Core offering

Freespira develops and sells an FDA-cleared at-home digital therapeutic that combines a proprietary breathing sensor, integrated tablet with real-time capnometry feedback software, and Care Specialist coaching to normalize dysfunctional breathing patterns and reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD in a 28-day protocol. The bundled treatment kit is shipped directly to patients' homes and is covered as a medical benefit by health plans, self-insured employers, and the VA.

Product overview

Freespira, Inc. offers a single unified digital therapeutic product—the Freespira system—for the treatment of panic disorder, panic attacks, and PTSD symptoms. The core offering consists of the Freespira hardware device (now in its fifth generation FST5) combined with a proprietary software application and coaching services. The system includes a compact breathing sensor, tablet with real-time feedback display, nasal cannula, and dedicated Care Specialist support. Treatment follows a 28-day protocol with twice-daily 17-minute sessions. After completing the program, patients receive the Freespira Tones App for continued practice. All components work together as an integrated at-home treatment solution that addresses the underlying physiological causes of anxiety disorders through breathing retraining.

Differentiator

Problem solved

Functional benefit

Products and services

  • Freespira Digital Therapeutic System (FST5) FDA-cleared at-home medical device that combines a proprietary breathing sensor with an integrated display tablet to provide real-time, feedback-guided respiratory retraining for adults and adolescents with panic disorder and PTSD.
  • Freespira 28-Day Treatment Protocol At-home treatment program requiring two 17-minute sessions per day for 28 days, using capnography-guided respiratory intervention (CGRI) to normalize breathing patterns and reduce or eliminate panic attacks and PTSD symptoms. Includes device kit, real-time biofeedback, virtual onboarding, and weekly Care Specialist check-ins. Indicated for adults and adolescents (ages 13+) with panic disorder or PTSD.

Quantifiable outcome

  • Over 80% of patients experienced significant symptom reduction post-treatment (panic disorder and PTSD combined)
  • +7 more outcomes

Companies that use Freespira, Inc.

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles4 records

Freespira, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Freespira, Inc. partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, secondary and minor.

  • Brighton MarinecoreStrategic or Co-development Partner · 1 December 2025Freespira partnered with Brighton Marine, a nonprofit administering the US Family Health Plan (USFHP) for Southern New England, to make its FDA-cleared digital therapeutic for panic disorder and PTSD available to Brighton Marine Health Plan members. The treatment became available in November 2025, representing Brighton Marine's commitment to providing veterans and military families with innovative mental health treatments.
  • WellCare of KentuckycoreStrategic or Co-development Partner · 1 May 2025WellCare of Kentucky (a Centene Medicaid plan) launched a pilot program with Freespira providing eligible Medicaid members access to at-home digital therapeutic treatment for panic disorder and PTSD. WellCare is the first health plan in Kentucky to partner with a digital therapeutic company specializing in mental health. Analytics estimate 12% of WellCare's 450,000 Kentucky Medicaid members could benefit.
  • Point32HealthcoreStrategic or Co-development Partner · 1 November 2022Point32Health (parent of Harvard Pilgrim Health Care and Tufts Health Plan) selected Freespira as winner of its inaugural Innovation Challenge, recognizing it as a pioneering solution for mental health outcomes and affordability. The partnership aims to pilot Freespira's treatment technology to expand mental health options for Point32Health's 2.2 million members in New England.
  • Highmark BCBScoreStrategic or Co-development PartnerHighmark BCBS expanded access to Freespira's digital therapeutic for panic disorder and PTSD across its member base. A Highmark behavioral health director cited reduced medication use and healthcare cost savings as drivers for the partnership.
  • Security Health PlansecondaryChannel Partner/ Reseller/ DistributorSecurity Health Plan selected Freespira as a new benefit offering for members with panic disorder and PTSD, integrating it into their covered mental health treatments.
  • Lovell Government ServicescoreChannel Partner/ Reseller/ DistributorFreespira is listed on the Federal Supply Schedule 65IIA #V797D-50450 through SDVOSB partner Lovell Government Services. Lovell facilitates VA procurement and handles the Government Services administration for Freespira's veteran treatment program. CAGE: 71G35, DUNS: 079230337, UEI: MNH3STM1FTS6.
  • Crossover HealthsecondaryChannel Partner/ Reseller/ DistributorCrossover Health is listed as a Freespira partner, likely offering the treatment to its member population through employer-sponsored health benefits.
  • Chorus PreferredsecondaryChannel Partner/ Reseller/ DistributorChorus Preferred is listed as a Freespira partner organization, potentially serving as a navigation platform or aggregator for the digital therapeutic.
  • IMPACT (Virtual First Medical Practice Collaborative)minorStrategic or Co-development PartnerFreespira is a founding member of IMPACT, the Virtual First Medical Practice Collaborative at the Digital Medicine Society, focused on advancing digital medicine and virtual-first care models.
  • New Vista (Kentucky)minorStrategic or Co-development PartnerNew Vista, a Kentucky-based organization specializing in integrated mental and physical healthcare, was designated as the key medical practice partner for WellCare of Kentucky's Freespira pilot program.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Freespira, Inc. competitors and assessment

Company assessment

Direct peers

  • Big Health: Big Health develops FDA-cleared prescription digital therapeutics (Sleepio for insomnia, Daylight for anxiety) sold through health plans and employers on outcomes-based contracts. Most directly comparable to Freespira in PDT business model, payor go-to-market, and clinical evidence positioning.
  • Akili Interactive: Akili markets EndeavorRx, an FDA-cleared prescription digital therapeutic (for ADHD) with similar payor reimbursement and clinical evidence strategy. Closest analog to Freespira among publicly known PDTs in regulatory pathway and business model.
  • Pear Therapeutics: Pear Therapeutics pioneered FDA-cleared prescription digital therapeutics (reSET, reSET-O) for substance use disorder and is the historical reference point for Freespira's PDT model, though it filed for bankruptcy in 2023 illustrating category capital risks.

Emerging players

  • Limbic: Limbic is a UK-based digital mental health platform offering AI-driven CBT and emotional support tools sold to health systems and payors. Comparable to Freespira as a technology-driven mental health intervention with payor channels, though focused on a different delivery modality.
  • Woebot Health: Woebot Health delivers AI chatbot-based mental health interventions with FDA Breakthrough Device designation. Comparable to Freespira as an emerging digital therapeutic in behavioral health with regulatory clearance pursuit, though software-only and consumer-focused.

Broad incumbents

  • Lyra Health: Lyra Health is a leading mental health benefits platform for employers, bundling therapy, coaching, and digital tools. Comparable to Freespira as a payor-facing mental health vendor, but operates as a broad incumbent across the full continuum of care rather than a single therapeutic.
  • Spring Health: Spring Health provides employer-sponsored mental health benefits combining provider networks, coaching, and digital programs. Comparable to Freespira as a payor channel for anxiety/PTSD care, but offers a broader, integrated solution set rather than a single device-based treatment.
  • Cerebral: Cerebral is a subscription-based mental health platform offering telehealth psychiatry and therapy for anxiety, depression, and related conditions. Comparable to Freespira in DTC marketing and anxiety-focused positioning, though broader in scope and provider-delivered.
  • Talkspace: Talkspace operates an online therapy platform sold through health plans and employers. Comparable to Freespira as a payor-covered mental health service targeting anxiety and trauma-related conditions, though therapy-delivered rather than device-based.
  • BetterHelp: BetterHelp (a Teladoc Health subsidiary) is the largest consumer-facing online therapy platform. Comparable to Freespira in serving patients with anxiety and PTSD symptoms via remote care, though broader in scope and pure-software in delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Freespira, Inc. social profiles

Digital presence

Freespira, Inc. compliance and trust

Trust signal

Compliance2 records

Freespira, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Freespira, Inc. leadership team

Management profile

Number of profiles

Profiles11 records

Freespira, Inc. funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Freespira, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Freespira, Inc.

What does Freespira, Inc. do?

Freespira develops and sells an FDA-cleared at-home digital therapeutic that combines a proprietary breathing sensor, integrated tablet with real-time capnometry feedback software, and Care Specialist coaching to normalize dysfunctional breathing patterns and reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD in a 28-day protocol. The bundled treatment kit is shipped directly to patients' homes and is covered as a medical benefit by health plans, self-insured employers, and the VA.

Is Freespira, Inc. a public or private company?

Freespira, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Freespira, Inc. founded?

Freespira, Inc. was founded in 2013. It employs 11 to 50 people.

Where is Freespira, Inc. based?

Freespira, Inc. is headquartered in Kirkland, United States, in the North America region.

How does Freespira, Inc. make money?

Four revenue lines are on record. Health Plan and Employer Benefit Coverage is the primary driver. The others are VA Federal Procurement, self-Pay / HSA/FSA / Payment Plans and outcomes-Based / Performance Pricing.

Who are Freespira, Inc.'s main competitors?

Direct peers on record are Big Health, Akili Interactive and Pear Therapeutics. Emerging players are Limbic and Woebot Health. Broad incumbents are Lyra Health, Spring Health, Cerebral, Talkspace and BetterHelp.

Does Freespira, Inc. have an API?

No public API is recorded for Freespira, Inc..

What industry is Freespira, Inc. in?

Freespira, Inc.'s product category is Digital Therapeutics. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs). Its NAICS code is 62161 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFreespira Introduces the Zero Risk Program for Health Plans, a First for Mental Health DevicesFreespira, Inc. announced the launch of its Zero Risk program for health plans, described as the first performance guarantee program offered by a behavioral health medical device maker. The program offers a 1:1 ROI performance guarantee in Year 1, outcomes-based pricing, member engagement support, and reduced administrative burden to encourage health plan adoption of its FDA-cleared at-home treatment for anxiety disorders. The announcement follows Freespira's recent FDA indication expansion to treat adolescents (13-17) and cites clinical data showing the treatment can reduce total medical costs by 35%.ZME ScienceYour Next Therapist Could be a Video Game or a Wearable and It Might Actually WorkA peer-reviewed study examines digital therapeutics like NightWare, Freespira, EndeavorRx, and Sleepio, which are FDA-cleared or NICE-approved for conditions such as PTSD, panic disorder, ADHD, and insomnia. The authors warn that privacy, access, and long-term efficacy remain unresolved issues. They call for stronger encryption, equitable design, and longer trials.PulmonologyadvisorFDA Clears Freespira Breathing System for Teens With Anxiety DisordersThe FDA has expanded approval for the Freespira Breathing System to treat panic disorder and PTSD symptoms in adolescents aged 13 to 17. Clinical trial data demonstrated a 54% reduction in panic disorder severity and a 44% reduction in PTSD severity among participants following a 28-day treatment protocol. The clearance allows teens to undergo this at-home, clinically validated therapy without disrupting their school schedules.STATFreespira bets on slow and steady, amid spectacular digital health collapsesFreespira, a developer of digital health treatments for panic and PTSD, is pursuing a strategy focused on steady patient growth and profitability rather than rapid adoption. The company recently raised $10 million to support product improvements and aims to break even by the end of 2025 while expanding its payer network.SecSEC FORM DFreespira, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates that the company raised a total of $22,578,792 from 14 investors, with no remaining amount left to be sold in this specific notice period.IforumrxOversight, Regulation, and Payment for Mobile Health AppsA University of Iowa pharmacy article reviews how mobile health apps are regulated in the U.S., noting that only a small subset meet the FDA's medical device definition and are subject to risk-based oversight. It lists 20 FDA-regulated prescription digital therapeutics, including EndeavorRx, Freespira, Insulia, Leva, and Mahana, and cites a $6.2 billion global PDTx market forecast to $32.5 billion by 2030.DtxallianceDTx Commercialization Launch Playbook Case StudyDigital Therapeutics Alliance announced the release of a new white paper in collaboration with Clearview Healthcare Partners, which presents a case study on Freespira. The paper examines critical success factors for a successful launch in the digital therapeutics landscape, targeting industry leaders, product launch professionals, and DTx enthusiasts. No pricing, publication date, or specific findings were disclosed.American Medical AssociationThe right mobile apps can help boost your patients’ mental healthThe American Medical Association and Digital Therapeutics Alliance hosted a webinar defining digital therapeutics as evidence-based software interventions for treating medical conditions, distinct from general wellness apps. The session highlighted specific clinical applications, including SparkRx for adolescent depression managed by physicians and Freespira Inc.'s FDA-cleared device for panic disorder.PR NewswireLovell and Freespira Increase Access to FDA-Cleared, Drug-Free PTSD Treatment for Veterans and Military PersonnelLovell Government Services announced a partnership with Freespira to distribute its FDA-cleared medical device for PTSD and panic disorder treatment through federal healthcare systems. This agreement allows the Veterans Health Administration, Military Health System, and Indian Health Services to provide the drug-free at-home treatment via existing government contract vehicles.PR NewswireFreespira an effective treatment for PTSD and panic disorder, real-world study confirmsFreespira, Inc. published a real-world outcomes study in Frontiers in Digital Health demonstrating the effectiveness of its FDA-cleared at-home digital therapeutic for treating panic disorder and PTSD, following more than 1,500 patients. The treatment achieved a 75% adherence rate across both patient groups, with a 65% response rate among 1,395 panic disorder patients and a 72% response rate among 174 PTSD patients. The company is actively expanding payer coverage and positioning Freespira as a viable medication-free treatment option alongside psychotherapy and medication.